WallStSmart

Cerus Corporation (CERS)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 16286% more annual revenue ($35.48B vs $216.56M). MDT leads profitability with a 13.0% profit margin vs -4.4%. MDT earns a higher WallStSmart Score of 61/100 (C+).

CERS

Avoid

31

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -5.79

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CERS.

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CERS1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
24.1%8/10

Revenue surging 24.1% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

CERS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$559.03M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.443/10

Elevated debt levels

Return on EquityProfitability
-14.1%2/10

ROE of -14.1% — below average capital efficiency

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : CERS

The strongest argument for CERS centers on Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : CERS

The primary concerns for CERS are EPS Growth, Market Cap, Debt/Equity.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CERS profiles as a growth stock while MDT is a value play — different risk/reward profiles.

CERS carries more volatility with a beta of 1.77 — expect wider price swings.

CERS is growing revenue faster at 24.1% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cerus Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?